Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bastien Mejias"'
Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
Autor:
Manon Penco-Campillo, Yannick Comoglio, Álvaro Javier Feliz Morel, Rita Hanna, Jérôme Durivault, Magalie Leloire, Bastien Mejias, Marina Pagnuzzi, Amandine Morot, Fanny Burel-Vandenbos, Matthew Selby, Daniel Williamson, Steven C. Clifford, Audrey Claren, Jérôme Doyen, Vincent Picco, Sonia Martial, Gilles Pagès
Publikováno v:
Communications Biology, Vol 3, Iss 1, Pp 1-1 (2020)
A Correction to this paper has been published: https://doi.org/10.1038/s42003-020-01502-2.
Externí odkaz:
https://doaj.org/article/ced1fd9a1ee94504bac7021a747121a7
Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
Autor:
Matthew Selby, Steven C. Clifford, Audrey Claren, Jérôme Doyen, Sonia Martial, Álvaro Javier Feliz Morel, Amandine Morot, Rita Hanna, Bastien Mejias, Yannick Comoglio, Magalie Leloire, Marina Pagnuzzi, Fanny Burel-Vandenbos, Vincent Picco, Manon Penco-Campillo, Jérôme Durivault, Gilles Pagès, Daniel Williamson
Publikováno v:
Communications Biology, Vol 3, Iss 1, Pp 1-1 (2020)
A Correction to this paper has been published: https://doi.org/10.1038/s42003-020-01502-2.
Autor:
Amandine Morot, Audrey Claren, Jérôme Doyen, Fanny Burel-Vandenbos, Steven C. Clifford, Manon Penco-Campillo, Rita Hanna, Matthew Selby, Bastien Mejias, Jérôme Durivault, Álvaro Javier Feliz Morel, Gilles Pagès, Sonia Martial, Magalie Leloire, Daniel Williamson, Marina Pagnuzzi, Yannick Comoglio, Vincent Picco
Publikováno v:
Communications Biology
Communications Biology, Vol 3, Iss 1, Pp 1-14 (2020)
Communications Biology, Nature Publishing Group, 2020, 3 (1), pp.579. ⟨10.1038/s42003-020-01306-4⟩
Communications Biology, Vol 3, Iss 1, Pp 1-14 (2020)
Communications Biology, Nature Publishing Group, 2020, 3 (1), pp.579. ⟨10.1038/s42003-020-01306-4⟩
Medulloblastoma (MB), the most common brain pediatric tumor, is a pathology composed of four molecular subgroups. Despite a multimodal treatment, 30% of the patients eventually relapse, with the fatal appearance of metastases within 5 years. The majo